Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FABP7 | O15540 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19857462 | 0.81 | HTT (0.50) | HTTMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL1171107 | 0.81 | MAPK1 (0.34) | HTTALDH1A1HSD17B10PRKCA | |
| SCHEMBL2692345 | 0.81 | HTT (0.50) | HTTMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL23005578 | 0.81 | HTT (0.50) | HTTMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL3095013 | 0.81 | LMNA (0.39) | HTTALDH1A1TSHRHSD17B10PRKCA | |
| SCHEMBL13610613 | 0.81 | POLB (0.40) | HTTMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL22915535 | 0.78 | HTT (0.48) | HTTMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL5362241 | 0.77 | HTT (0.46) | HTTMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL5355110 | 0.77 | HTT (0.46) | HTTMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL28024337 | 0.77 | HTT (0.46) | HTTMEN1ALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025932-A1 | NOVEL FUNCTIONALIZED LACTONES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025932-A1 | NOVEL FUNCTIONALIZED LACTONES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR2C, HTR3A | HTT 1551/4885MEN1 3075/4885ALDH1A1 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.